Sign In
Section Navigation
Common TitleBI-1182.33
Official Title A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks
Phase Phase II
ClinicalTrials.gov NCT00144105
Treatments
Lopinavir-Ritonavir
Lopinavir-Ritonavir Kaletra

Lopinavir-Ritonavir

Tradename:KaletraOther Names:LPV-RTVClass:Protease Inhibitors (PI)
,
Tipranavir
Tipranavir Aptivus

Tipranavir

Tradename:AptivusOther Names:TPVClass:Protease Inhibitors (PI)
,
Ritonavir
Ritonavir Norvir

Ritonavir

Tradename:NorvirOther Names:RTVClass:Pharmacokinetic Enhancers
Categories PharmacologyTreatment-NaiveAdverse Effects
Funding
IndustryBoehringer Ingelheim
References
  • Carr A, Ritzhaupt A, Zhang W, et al. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS. 2008;22:2313-21.
    [PubMed Abstract]
  • Cooper DA, Cordery DV, Zajdenverg R, et al. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. PLoS One. 2016;11:e0144917.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.